Sam Gandy
Viewpoint: Why the FDA’s decision to overrule its evaluatory panel and approve dementia-relief drug Aduhelm was a mistake
Like many people, I was shocked when the Food and Drug Administration ignored the advice of its neurological drugs advisory ...